Prolapse surgery — structured SAQ (15 marks)

(a) POP-Q diagnosis and apical support status (2 marks)

One mark for the diagnosis and one for the apical statement. ^[1]

• Diagnosis: Stage III anterior compartment prolapse — leading edge 3 cm below the hymen with Ba at +3 cm; the leading point is more than 1 cm below the hymen but no further than TVL − 2 cm. ^[1]
• Apical support: Mild apical loss — point C at −2 cm indicates the cervix is descended but the apex is not at or beyond the hymen; the apical compartment is failing alongside the anterior compartment and must be addressed to prevent recurrence. ^[1]

(b) Route-based procedure choice (5 marks)

One mark for naming the apical procedure; one mark each for the trade-offs in sacrocolpopexy, vaginal apical suspension and colpocleisis; one mark for the chosen route matched to her priorities. ^[2]

• Apical first. Even when the leading bulge is anterior, the apex is failing; an anterior repair alone will recur at the apex. ^[2]
• Sacrocolpopexy (abdominal/laparoscopic/robotic) — durability benchmark for apical prolapse (Maher 2023 RR 2.31 for awareness of prolapse after vaginal apical procedures); abdominal mesh category; longer recovery and abdominal entry. ^[2]
• Vaginal apical suspension — sacrospinous or uterosacral — avoids abdominal entry; shorter recovery; higher apical recurrence at 5 years than sacrocolpopexy; mandatory cystoscopy for ureteric patency after uterosacral suspension. ^[2]
• Colpocleisis (Le Fort partial or total) — highly effective, low morbidity and short recovery, but permanently closes or shortens the vagina and forecloses penetrative intercourse. Inappropriate here because she is sexually active and the apex is not yet at the hymen. ^[2]
• Chosen route: A laparoscopic or robotic sacrocolpopexy with anterior repair offers durability for the apical failure while preserving the vaginal axis and sexual function; alternatively, a vaginal apical suspension with anterior repair is acceptable if she declines an abdominal operation. ^[2]

(c) Mesh consent including the regulatory context (3 marks)

One mark for the abdominal sacrocolpopexy mesh category; one mark for the transvaginal mesh kit withdrawal; one mark for the conversation specifics. ^[3][4]

• Abdominal sacrocolpopexy mesh is in a different regulatory category — it remains a standard apical option and is not affected by the transvaginal mesh withdrawal. ^[4]
• Transvaginal mesh kits for POP were removed from the Australian Register of Therapeutic Goods in November 2017; the FDA ordered manufacturers to stop selling transvaginal mesh for POP in April 2019; the Cochrane (Yeung 2024) shows no clear benefit over native tissue and added morbidity. ^[3][4]
• Document mesh exposure (vaginal), erosion into bladder or bowel, sacral discitis, chronic pain and reoperation on the consent form; record the route and the mesh brand; explain that midurethral slings for stress incontinence are a separate category and that sacrocolpopexy mesh is the abdominal, not the transvaginal, category. ^[3][4]

(d) Postoperative care (3 marks)

One mark each for voiding, recurrence surveillance and sexual function. ^[2]

• Voiding assessment — voiding trial before discharge; document post-void residual; teach self-catheterisation if retained volume exceeds the local threshold; arrange six-week wound and voiding review. ^[2]
• Recurrence surveillance — review at six weeks, six months and twelve months; counsel that anatomical recurrence is not the same as symptomatic reoperation; teach the patient to report a new bulge, voiding change or dyspareunia; document pelvic-floor exercise for life. ^[2]
• Sexual function conversation — most patients improve when the bulge resolves; de novo dyspareunia or pelvic pain may persist, particularly after posterior repair or with mesh; provide topical oestrogen if atrophic; offer early review if symptoms develop. ^[2]

(e) Reoperation rate and long-term anatomic predictor (2 marks)

One mark for the rate and one for the predictor, both with citations. ^[5][6]

• Reoperation rate after prolapse or incontinence surgery is approximately 29% over a woman's lifetime (Olsen 1997) — repeat surgery is real and worth discussing before the first operation. ^[6]
• Long-term anatomic predictor — levator ani avulsion visible on translabial ultrasound (Atan 2018): OR ≈ 2.6 for clinically significant POP at 20+ years after the first vaginal birth; explains why some "anterior" repairs recur at the apex. ^[5]

Common errors that lose marks

• Calling the prolapse Stage II because the bulge is "near the hymen" — Stage III is more than 1 cm below the hymen; Ba at +3 cm is Stage III. ^[1]
• Offering anterior repair alone without supporting the apex — apical failure is the predictable next step. ^[2]
• Treating abdominal sacrocolpopexy mesh and transvaginal mesh kits as the same regulatory category — they are not. ^[3][4]
• Recommending colpocleisis to a sexually active patient without explaining loss of penetrative intercourse. ^[2]
• Skipping the voiding trial and recurrence surveillance plan. ^[2]

Examiner notes

The candidate who scores well describes the route-based choice, names the apical failure, defends sacrocolpopexy against vaginal apical suspension with the Maher 2023 numbers, and writes a consent conversation that separates transvaginal mesh kits from abdominal sacrocolpopexy mesh. The candidate who scores poorly offers an anterior repair without apical thought, treats the two mesh categories as one, or fails to address the sexual function and recurrence plan. ^[2][3][4]